How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

28,359 results for

Alcoholic Hepatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis

Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2018 Clinical Trials

122. Liver transplantation for severe alcoholic hepatitis: where are we now? (PubMed)

Liver transplantation for severe alcoholic hepatitis: where are we now? 30218596 2019 03 12 2019 03 12 1527-6473 24 10 2018 10 Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society Liver Transpl. Liver Transplantation for Severe Alcoholic Hepatitis: Where Are We Now? 1327-1328 10.1002/lt.25337 Gelu-Simeon Moana M Centre Hospitalier Universitaire Guadeloupe, Université des Antilles, Service (...) d'Hépato-Gastroentérologie, Pointe-à-Pitre, Guadeloupe. INSERM, Unités Mixtes de Recherche en Santé1085/IRSET, Rennes, France. Mathurin Philippe P Service des Maladies de l'Appareil Digestif, Hôpital Huriez, CHRU Lille, Université Lille 2, INSERM U795, Lille, France. eng Editorial Comment United States Liver Transpl 100909185 1527-6465 IM Liver Transpl. 2018 Oct;24(10):1357-1362 30141270 Hepatitis, Alcoholic Humans Liver Transplantation Patient Selection Recurrence Surveys and Questionnaires 2018 09 10

2018 Liver Transplantation

123. Grand Rounds: Alcoholic Hepatitis. (PubMed)

Grand Rounds: Alcoholic Hepatitis. A 33-year-old Caucasian male was admitted to hospital with recent onset of jaundice of 2-3 weeks duration. He reported heavy use of alcohol for the last 10 years with the last drink a day prior to the onset of symptoms. At admission, he was alert and oriented to time, place, and person, and was deeply jaundiced. His laboratory profile can be summarised as follows: haemoglobin 12.1 g/dl, white blood cell count 18,700 with 81% neutrophils, serum bilirubin 33 (...) (direct 22) mg/dl, aspartate aminotransferase 147 IU/L, alanine aminotransferase 62 IU/L, alkaline phosphatase 117 IU/L, serum albumin 2.8 gm/dl, serum creatinine 0.6 mg/dl, prothrombin time 18.3 (control 14.5) seconds, and international normalized ratio 1.48. He was diagnosed with severe alcoholic hepatitis (Maddrey discriminant function score of 50) and treated with prednisolone for 28 days with symptomatic and biochemical improvement. His Lille score at seven days was 0.4, and his serum bilirubin

2018 Journal of Hepatology

124. Advances in the treatment of severe alcoholic hepatitis. (PubMed)

Advances in the treatment of severe alcoholic hepatitis. Severe alcoholic hepatitis (SAH) is a costly and worldwide public health issue with high morbidity and mortality. Specific effective treatments for SAH have yet to be established. The aim of the present article is to review the current knowledge of the pathogenesis, assessment and treatment options in patients with SAH. To date, alcohol abstinence and enteral nutrition are the recommended first-line treatments. Although corticosteroids

2018 Current medical research and opinion

125. Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. (PubMed)

Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Chronic liver disease has negative effects on health-related quality of life (HRQL). We analyzed data from the European non-alcoholic fatty liver disease (NAFLD) registry to assess the effects of NAFLD on HRQL.We collected data from 304 patients (mean age, 52.3±12.9 years) with histologically defined NAFLD enrolled prospectively into the European NAFLD Registry in Germany, the United

2018 Clinical Gastroenterology and Hepatology

126. Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis. (PubMed)

Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis. Chronic liver diseases are characterized by the expansion of ductular reaction (DR) cells and the expression of liver progenitor cell (LPC) markers. In alcoholic hepatitis (AH), the degree of DR expansion correlates with disease progression and short-term survival. However, little is known about the biological properties of DR cells, their impact on the pathogenesis of human liver disease (...) , and their contribution to tissue repair. In this study, we have evaluated the transcriptomic profile of DR cells by laser capture microdissection in patients with AH and assessed its association with disease progression. The transcriptome analysis of cytokeratin 7-positive (KRT7+ ) DR cells uncovered intrinsic gene pathways expressed in DR and genes associated with alcoholic liver disease progression. Importantly, DR presented a proinflammatory profile with expression of neutrophil recruiting C-X-C motif chemokine

2018 Hepatology

127. Transplantation for Alcoholic Hepatitis: Are We Achieving Justice and Utility? (PubMed)

Transplantation for Alcoholic Hepatitis: Are We Achieving Justice and Utility? Early liver transplantation for alcoholic hepatitis is a potentially life-saving treatment. As this practice becomes increasingly common, however, the liver transplant community is taking a fresh look at a familiar challenge: best stewardship of donor organs. Herein, we examine a few basic, necessary ethical and practical concerns relevant to this indication.© 2018 by the American Association for the Study of Liver

2018 Hepatology

128. Arid1a loss drives non-alcoholic steatohepatitis in mice via epigenetic dysregulation of hepatic lipogenesis and fatty acid oxidation. (PubMed)

Arid1a loss drives non-alcoholic steatohepatitis in mice via epigenetic dysregulation of hepatic lipogenesis and fatty acid oxidation. Nonalcoholic steatohepatitis (NASH) is a rapidly growing cause of chronic liver damage, cirrhosis, and hepatocellular carcinoma (HCC). How fatty liver pathogenesis is subject to epigenetic regulation is unknown. We hypothesized that chromatin remodeling is important for the pathogenesis of fatty liver disease. ARID1A, a DNA-binding component of the SWI/SNF ATP (...) mice were more susceptible to high-fat diet-induced liver steatosis and fibrosis. We deleted Pten in combination with Arid1a to synergistically drive fatty liver progression. Inhibition of lipogenesis using CAT-2003, a potent SREBP inhibitor, mediated improvements in markers of fatty liver disease progression in this Arid1a/Pten double knockout model. CONCLUSION: ARID1A plays a role in the epigenetic regulation of hepatic lipid homeostasis, and its suppression contributes to fatty liver

2018 Hepatology

129. IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH)

IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH) IL-1 Signal Inhibition in Alcoholic Hepatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH (...) Pharmaceuticals Information provided by (Responsible Party): Imperial College London Study Details Study Description Go to Brief Summary: Alcoholic hepatitis (AH) is a florid presentation of alcoholic liver disease characterized by liver failure in the context of recent and heavy alcohol consumption. The condition carries a high fatality risk; patients with severe AH have a 30% mortality rate at 90 days after presentation. Currently there is no effective treatment for severe alcoholic hepatitis. Based on our

2018 Clinical Trials

130. Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial. (PubMed)

Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial. Alcoholic hepatitis (AH) has the most severe presentation among alcohol-related liver diseases. Corticosteroids are the most widely recommended treatment for severe AH. However, more innovative, refined treatment measures are required because of its high mortality despite corticosteroid treatment

Full Text available with Trip Pro

2018 Trials Controlled trial quality: uncertain

131. Noncholesterol Sterols as Surrogate Markers in Patients with Severe Alcoholic Hepatitis. (PubMed)

Noncholesterol Sterols as Surrogate Markers in Patients with Severe Alcoholic Hepatitis. Severe alcoholic hepatitis (AH) is a life-threatening condition lacking good serologic markers to tailor treatment and predict recovery. We examined the cholesterol metabolism in severe AH to explore prognostic markers and evaluate the profile of cholesterol precursors, cholestanol and phytosterols, in this context. We assessed serum cholesterol, cholesterol precursors, cholestanol, phytosterols

2018 Lipids Controlled trial quality: uncertain

132. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. (PubMed)

Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. 29385313 2018 05 01 2018 12 02 1527-6473 24 5 2018 05 Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society Liver Transpl. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. 711 10.1002 (...) /lt.25026 Sussman Norman L NL Abdominal Transplant and Liver Disease Clinic, Baylor College of Medicine, Houston, TX. Kelly James H JH Cell Machines, Inc., Houston, TX. eng Letter Comment 2018 04 06 United States Liver Transpl 100909185 1527-6465 IM Liver Transpl. 2018 Mar;24(3):380-393 29171941 Hepatitis, Alcoholic Humans Liver Transplantation Prospective Studies 2017 12 25 2018 01 29 2018 2 1 6 0 2018 5 2 6 0 2018 2 1 6 0 ppublish 29385313 10.1002/lt.25026

Full Text available with Trip Pro

2018 Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society Controlled trial quality: uncertain

133. Time course of compromised urea synthesis in patients with alcoholic hepatitis. (PubMed)

Time course of compromised urea synthesis in patients with alcoholic hepatitis. Alcoholic hepatitis (AH) markedly decreases the urea synthesis capacity. We aimed to investigate the time course of this compromised essential liver function in patients with AH and its relation to treatment and survival.Thirty patients with AH were included in a prospective cohort study. We measured the substrate-independent urea synthesis capacity, i.e., the functional hepatic nitrogen clearance (FHNC (...) ), in the patients at study entry and again at three months (survivors/available: n = 17). Patients with severe disease (Glasgow Alcoholic Hepatitis Score ≥9, n = 17) were randomized to receive either prednisolone or pentoxifylline and were in addition examined after 14 days (n = 9).FHNC (normal range = 25-45 L/h) was markedly decreased at study entry (median = 5.6 (IQR = 3.0-9.6) L/h) and increased by three-fold in survivors at three months (15.1 (12.0-22.9) L/h; p < .001). In patients with severe AH, FHNC

2018 Scandinavian journal of gastroenterology Controlled trial quality: uncertain

134. Evidence for a role of genetics in alcoholic hepatitis: Data from the STOPAH randomized controlled trial. (PubMed)

Evidence for a role of genetics in alcoholic hepatitis: Data from the STOPAH randomized controlled trial. 28412295 2018 12 14 2018 12 14 1600-0641 67 1 2017 07 Journal of hepatology J. Hepatol. Evidence for a role of genetics in alcoholic hepatitis: Data from the STOPAH randomized controlled trial. 12-14 S0168-8278(17)30210-6 10.1016/j.jhep.2017.04.001 Louvet Alexandre A Service des maladies de l'appareil digestif, Hôpital Huriez, Lille, France. Electronic address: alexandre.louvet@chru (...) -lille.fr. Peck-Radosavljevic Markus M Abteilung Gastroenterologie & Hepatologie, Endokrinologie und Nephrologie, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria. Electronic address: markus@peck.at. eng Editorial Comment 2017 04 13 Netherlands J Hepatol 8503886 0168-8278 IM J Hepatol. 2017 Jul;67(1):120-127 28161471 Hepatitis, Alcoholic Homozygote Humans 2017 03 14 2017 03 27 2017 04 04 2017 4 17 6 0 2018 12 15 6 0 2017 4 17 6 0 ppublish 28412295 S0168-8278(17)30210-6 10.1016/j.jhep.2017.04.001

2018 Journal of Hepatology Controlled trial quality: uncertain

135. The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. (PubMed)

The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. Among patients with hepatitis C virus (HCV) infection, alcohol synergistically increases the risk of cirrhosis, hepatocellular carcinoma, and death. Randomized controlled trials of integrated models of HCV-alcohol treatment have been recommended but only performed in patients with severe alcohol use disorders.This pragmatic randomized controlled trial seeks (...) to compare clinical effectiveness and cost-effectiveness of integrated alcohol treatment compared to enhanced treatment as usual (TAU) on alcohol consumption and economic outcomes among patients ever infected with HCV.Patients recruited from three liver centers who had current or prior chronic HCV and qualifying alcohol screener scores were randomly assigned to enhanced TAU or the Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention. All patients received enhanced TAU, consisting of a patient

Full Text available with Trip Pro

2018 Contemporary clinical trials Controlled trial quality: uncertain

136. The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease. (PubMed)

The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease. The short chain fatty acid (SCFA) propionate, produced through fermentation of dietary fibre by the gut microbiota, has been shown to alter hepatic metabolic processes that reduce lipid storage. We aimed to investigate the impact of raising colonic propionate production on hepatic steatosis in adults with non-alcoholic fatty liver disease (NAFLD (...) % ± 6.8%; P = 0.635; n = 9). The predominant SCFA from colonic fermentation of inulin is acetate, which, in a background of NAFLD and a hepatic metabolic profile that promotes fat accretion, may provide surplus lipogenic substrate to the liver. The increased colonic delivery of propionate from IPE appears to attenuate this acetate-mediated increase in IHCL.© 2018 John Wiley & Sons Ltd.

2018 obesity & metabolism Controlled trial quality: uncertain

137. A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, randomized, Placebo-Controlled Study (PubMed)

A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, randomized, Placebo-Controlled Study Considering the recent interest in free (unconjugated) curcuminoids delivery, the present study investigated the efficacy of a novel food-grade free-curcuminoids delivery system (curcumin-galactomannoside complex; CGM) in improving the hepatic function markers (inflammation and oxidative stress) in chronic alcoholics (...) from the significant increase (p <0.001) in endogenous antioxidants (GSH, SOD, and GPx) and decrease in inflammatory markers (IL-6 and CRP) levels (p <0.001) as compared to both the baseline and placebo group. To summarize, the nutritional intervention of CGM-curcumin was found to offer a significant hepatoprotective effect to attenuate the alcohol induced alterations to hepatic function markers. The Indian Medical Council and Drug Controller General of India approved Clinical Trial Registry

Full Text available with Trip Pro

2018 BioMed research international Controlled trial quality: uncertain

138. Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. (PubMed)

Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. To investigate the effects of dapagliflozin on liver steatosis and fibrosis evaluated in patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).In a randomized, active-controlled, open-label trial, 57 patients with type 2 diabetes and NAFLD were randomized to a dapagliflozin group (...) (5 mg/d; n = 33) or a control group (n = 24) and were treated for 24 weeks. Hepatic steatosis and fibrosis were assessed using transient elastography to measure controlled attenuation parameter (CAP) and liver stiffness, respectively.Baseline liver stiffness measurement (LSM) was positively correlated with several markers and scoring systems for liver fibrosis. In week 24, there was a significant decrease in CAP from 314 ± 61 to 290 ± 73 dB/m (P = 0.0424) in the dapagliflozin group, while

2018 obesity & metabolism Controlled trial quality: uncertain

139. Efficacy of Granulocyte Colony Stimulating Factor and N-acetyl Cysteine Therapies in Patients with Severe Alcoholic Hepatitis. (PubMed)

Efficacy of Granulocyte Colony Stimulating Factor and N-acetyl Cysteine Therapies in Patients with Severe Alcoholic Hepatitis. Patients with alcoholic hepatitis (AH) have high mortality, so new therapies are needed. Administration of granulocyte colony stimulating factor (G-CSF) increases survival times of patients with AH. It is not known whether addition of N-acetyl cysteine (NAC) to G-CSF could further increase survival time. We performed a randomized controlled pilot study to compare

2018 Clinical Gastroenterology and Hepatology Controlled trial quality: predicted high

140. Improvement of Hepatic Fibrosis and Patient-Reported Outcomes in Non-Alcoholic Steatohepatitis Treated with Selonsertib. (PubMed)

Improvement of Hepatic Fibrosis and Patient-Reported Outcomes in Non-Alcoholic Steatohepatitis Treated with Selonsertib. Patient-reported outcomes (PROs) represent patients' perspective about their well-being.To assess PRO changes in patients with non-alcoholic steatohepatitis (NASH) after treatment with selonsertib (SEL) and to associate them with different biomarkers.Patients with NASH and stage 2-3 fibrosis received SEL 6 mg or 18 mg orally QD alone or in combination with simtuzumab (SIM (...) -0.24 to -0.38, P < .05).A decrease in hepatic collagen is the most prominently associated with improvement of PROs in NASH patients with F2-F3 treated with SEL. Furthermore, serum cytokines are associated with baseline PROs and with treatment-emergent changes in PROs in patients with NASH.© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

2018 Liver International Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>